Moreover, the stable expression of α-La during tumor development in TNBC-bearing mice as well as the induction of inflammatory T-cell responses in human PBMCs primed with recombinant α-La [125] suggest α-La as a suitable therapeutic cancer vaccine candidate. The gene discussed is SSB; the disease is neoplasm.